Irvine-based Edwards Lifesciences Corp. today announced newly presented data from several of its clinical trials.
The data, presented at the annual New York Valves 2026 conference, included seven-year benchmark results from its Partner 3 trial, as well as new findings from its Early TAVR trial.
Both trials are using Edwards’ Sapien 3 transcatheter heart valve and “strengthen the evidence base” for the platform, according to the company.
“Our expanding evidence base reflects Edwards’ clear and sustained commitment to advancing care through partnership with the physician community,” Chief Executive Bernard Zovighian said in a statement.
Shares in Edwards rose 2.3% to $91.76 apiece and a $52.8 billion market cap (NYSE: EW).
For more on Edwards, see the June 29 print edition of the Business Journal.
Related links:
